CA-GLOBALLOGIC-INC.
11.1.2023 12:01:37 CET | Business Wire | Press release
GlobalLogic Inc., a Hitachi Group company and Digital Engineering leader, announced today that it has been named an overall Leader in the Zinnov Zones for ER&D Services 2022 Ratings. The report provides a 360-degree assessment of engineering research and development (ER&D) service providers, identifying their prowess and scalability across key markets and technologies. It is leveraged by company decision makers seeking to identify vetted service providers to support a wide range of engineering projects. Such resources are increasingly more important as investment in digital transformation rises rapidly across all industries to satisfy a growing demand for intelligent, connected, and data-driven experiences for consumers and company employees alike.
Zinnov is a global management consulting and strategy advisory firm with 20+ years of experience. As part of its annual ER&D Services Zinnov Zones ratings exercise, the company evaluates more than 50 global service providers across multiple verticals, micro-verticals, and geographies. GlobalLogic’s earned position as an overall leader indicates the digital engineering firm has demonstrated itself to be an Established, Expansive company when compared to its peers—labels specifically measuring:
- Established: proven specialization; R&D practice maturity (depth and maturity of services); innovation and IP; ecosystem linkages
- Expansive: scale and scalability; number of verticals serviced; client spread/diversification
Validating its overall leadership recognition, GlobalLogic was rated in the leadership zone for the following verticals and technologies:
- Automotive
- Consumer Software
- Data & AI Engineering
- Enterprise Software
- Experience Engineering
- Telecommunications
- Telehealth
The 2022 edition of the Zones ratings marks GlobalLogic’s seventh year earning a spot in the ER&D Services Ratings’ general leader quadrant, having first placed there in 2016. While GlobalLogic first moved to an overall leadership position three years ago, it has since moved up in its rating and earned higher leadership zone positions in several sub-categories listed above.
“The recognition received in the Zinnov Zones evaluation is a direct testament to the ingenuity, commitment, and skills displayed by our team members around the world,” said Arya Barirani, Chief Marketing Officer, GlobalLogic. “From our perspective, this rating acknowledges our continued ability to deepen our foothold in a wide variety of markets. It also acknowledges our dedication to broadening our experience in technologies that drive next- gen digital transformations. These investments in our people, training, and facilities are all designed to help us better serve our customers.”
Sidhant Rastogi, Managing Partner, Zinnov, said, “GlobalLogic’s intense focus on building new-age technology capabilities, combined with its digital accelerators and its self-contained innovation labs, has helped the firm drive high value transformation for its customers. GlobalLogic continues to strengthen its digital core through strategic acquisitions like Fortech, which has enabled it to expand its portfolio of offerings across technologies and geographies. A well-articulated growth strategy and a data-driven approach across its wide-spectrum of Digital Engineering Services offerings has helped GlobalLogic firmly anchor its leadership position in the 2022 Zinnov Zones ER&D ratings.”
The 2022 ER&D Services Ratings report as well as prior year reports can be found here: https://zinnovzones.com/ratings/e-r-and-d-services/overall/2022.
About Zinnov
Founded in 2002, Zinnov is a global management consulting and strategy advisory firm with a presence in New York, Santa Clara, Seattle, Houston, Bangalore, Gurgaon, Paris, and Pune. With a team of experienced consultants, subject matter experts, and research professionals, Zinnov has partnered with Global Enterprises, Fortune 2000 companies, Global System Integrators, and Private Equity firms across their value creation journeys to develop actionable insights – across revenue, talent, innovation, scale, and optimization. For more information, visit Zinnov.
About GlobalLogic
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom